AcuCort has previously reported that EPO intended to approve the EU patent application No. 15790542.3. The patent primarily describes the formulation, the manufacturing process and the intended area of use for ISICORT®. The now granted patent will be validated and provide protection in 16 European countries including Turkey until November 2035.

In addition to Europe, the corresponding patent applications have been filed in the US, Japan, China, Hong Kong, Canada, Brazil and Australia.

AcuCort's drug candidate ISICORT® is already protected by the patent "Acute Glucocorticoid Therapy". This patent describes medical self-treatment with glucocorticoids in emergency situations when no medical personnel is available. The patent is granted in 31 countries, including in Europe and the US, and is valid to 2025, except in the US, where it is valid until the end of 2028.

"This is expected and very good news. AcuCort already has patent protection for the company's drug candidate ISICORT® in Europe, but the new patent `Dexamethasone ODF' granted by the European Patent Office means broader protection as well an extended term of protection. This will facilitate the commercialization of ISICORT®", says Mats Lindfors, CEO of AcuCort AB.